dabigatran has been researched along with Kidney Diseases in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (76.32) | 24.3611 |
| 2020's | 9 (23.68) | 2.80 |
| Authors | Studies |
|---|---|
| Fiaccadori, E; Italiano, C; Pacchiarini, MC; Rossi, GM; Vizzini, G | 1 |
| Biederman, L; Brodsky, SV; Ivanov, I; Kerlin, BA; Medipally, A; Parikh, S; Rovin, B; Satoskar, AA; Xiao, M | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kiss, RG; Kleine, E; Lip, GYH; Navarro Estrada, JL; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM | 1 |
| Balabanova, Y; Brobert, G; Fatoba, S; Fernandez, O; García Rodríguez, LA; Roberts, L; Ruigómez, A; Vora, P | 1 |
| Derebail, VK; Kerlin, BA; Rheault, MN | 1 |
| Berteotti, M; Casciaro, MA; Ettorre, E; Godino, C; Lip, GYH; Marcucci, R; Melillo, F; Menafra, V; Menichelli, D; Pastori, D; Perticone, F; Pignatelli, P; Saliola, M; Sciacqua, A; Violi, F | 1 |
| Bar, M; Bernstein, RA; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Gdovinová, Z; Granger, CB; Grauer, C; Kleine, E; Kleinig, TJ; Lyrer, P; Martins, S; Meyerhoff, J; Milling, T; Pfeilschifter, W; Poli, S; Reif, M; Rose, DZ; Sacco, RL; Šaňák, D; Schäbitz, WR | 1 |
| Brown, JD; Cristofoletti, R; Farhan, N; George, JM; Gordon, LA; Hadigan, C; Kim, S; Kumar, P; Lingineni, K; Penzak, S; Schmidt, S | 1 |
| Annaldas, S; Godugu, C; Saifi, MA | 1 |
| Abdelgawwad, K; Brescia, CW; Coleman, CI; Costa, OS; O'Donnell, B; Sood, N; Vardar, B | 1 |
| Abdel-Bakky, MS; Abo-Saif, AA; Alharbi, KS; Altowayan, WM; Bayoumi, AMA; Ewees, MGE; Messiha, BAS | 1 |
| Gersh, BJ; Nath, KA; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Tangri, N; Yao, X | 1 |
| Becker, M; Ganter, C; Hegemann, I; Müller, D; Spahn, DR; Widmer, CC | 1 |
| Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M | 1 |
| Doki, K; Homma, M; Neuhoff, S; Rostami-Hodjegan, A | 1 |
| Buch, TN; Holm, J; Munck, LK | 1 |
| Chana, F; Llau, JV; Marco, P; Zamorano, JL | 1 |
| Berns, JS; Chaknos, CM; Knauf, F; Perazella, MA | 1 |
| Waks, JW; Zimetbaum, PJ | 1 |
| Bajorek, B; Wang, Y | 1 |
| Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
| Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R | 1 |
| Altın, C; Gezmiş, E; Müderrisoğlu, H; Sakallıoğlu, O | 2 |
| Bayramoğlu, Z; Caynak, B; Karahan, O; Oral, MK; Sagbas, E; Unal, M; Yazici, S | 1 |
| Lane, DA; Wood, K | 1 |
| Karahan, O | 1 |
| Ge, D; Morrill, AM; Willett, KC | 1 |
| Behrendt, V; Gold, R; Hoepner, R; Krogias, C; Meves, S | 1 |
| Benöhr, P; Hohmann, C; Neumann-Haefelin, T; Radziwill, R | 1 |
| Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Huisman, MV; Kooiman, J; van de Peppel, WR; van der Meer, FJ | 1 |
| Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A | 1 |
| Hariharan, S; Madabushi, R | 1 |
| Connolly, SJ; Dansirikul, C; Ezekowitz, MD; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A; Wallentin, L; Yusuf, S | 1 |
| Dumenil, AS; Galbois, A; Lillo-Le Louët, A; Offenstadt, G; Samama, MM; Soufir, L; Wolf, M | 1 |
| Alvarez, M; de Gea-García, JH; Jiménez-Parra, JD; Ruiz-Villa, G | 1 |
5 review(s) available for dabigatran and Kidney Diseases
| Article | Year |
|---|---|
Role of direct oral anticoagulants in patients with kidney disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Diseases; Prospective Studies; Retrospective Studies | 2020 |
[New clinical perspectives in the management of oral direct anticoagulant agents].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2014 |
Dabigatran and kidney disease: a bad combination.
Topics: Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation Tests; Charcoal; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Kidney Diseases; Plasma; Renal Replacement Therapy | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
4 trial(s) available for dabigatran and Kidney Diseases
| Article | Year |
|---|---|
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Topics: Aged; Aged, 80 and over; Aspirin; Dabigatran; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Intracranial Embolism; Kidney Diseases; Male; Middle Aged; Recurrence; Stroke | 2020 |
Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
Topics: Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Computer Simulation; Dabigatran; Female; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Young Adult | 2012 |
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Body Weight; Dabigatran; Drug Interactions; Ethnicity; Hemoglobins; Humans; Kidney Diseases; Middle Aged; Models, Theoretical; Pharmacokinetics; Plasma; Prodrugs; Pyridines; Thrombin; Young Adult | 2011 |
29 other study(ies) available for dabigatran and Kidney Diseases
| Article | Year |
|---|---|
Atheroembolic renal disease associated with dabigatran overdose.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Overdose; Humans; Kidney Diseases | 2022 |
Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity.
Topics: Animals; Anticoagulants; Creatinine; Dabigatran; Endothelial Cells; Glomerular Filtration Barrier; Hematuria; Kidney Diseases; Rats; Receptor, PAR-1 | 2022 |
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Kidney Diseases; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; United Kingdom | 2019 |
Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Rivaroxaban; Stroke | 2020 |
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cobicistat; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Risk Assessment; Ritonavir | 2021 |
A direct thrombin inhibitor, dabigatran etexilate protects from renal fibrosis by inhibiting protease activated receptor-1.
Topics: Animals; Antithrombins; Collagen Type I; Dabigatran; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Oxidative Stress; Receptor, PAR-1; Signal Transduction; Snail Family Transcription Factors; Transforming Growth Factor beta; Ureteral Obstruction | 2021 |
Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus, Type 2; Electronic Health Records; Eye Diseases; Humans; Kidney; Kidney Diseases; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway.
Topics: Animals; Antithrombins; Apoptosis; Blood Urea Nitrogen; Caspase 3; Cisplatin; Dabigatran; Down-Regulation; Kidney; Kidney Diseases; Male; MAP Kinase Signaling System; Neoplasms; Oxidative Stress; Rats; Thrombin; Tumor Suppressor Protein p53 | 2021 |
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; International Normalized Ratio; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2017 |
Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation Tests; Dabigatran; Emergency Medical Services; Female; Gastrointestinal Hemorrhage; Humans; Kidney Diseases | 2018 |
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2019 |
Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Kidney Diseases; Models, Theoretical; Prodrugs; Verapamil | 2019 |
[Extensive thromboembolism after cardioversion in a patient treated with dabigatran].
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Electric Countershock; Humans; Ileus; Kidney Diseases; Male; Risk Factors; Thromboembolism; Tomography, X-Ray Computed; Vitamin K | 2013 |
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Female; Half-Life; Hemorrhage; Humans; Kidney Diseases; Male; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Kidney Diseases; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; Socioeconomic Factors; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
A novel oral anticoagulant, dabigatran, in acute renal infarction.
Topics: Anticoagulants; Cardiac Catheterization; Cardiomyopathy, Dilated; Dabigatran; Diagnosis, Differential; Humans; Kidney Diseases; Male; Middle Aged; Tomography, X-Ray Computed; Venous Thrombosis | 2015 |
Comparison of Renoprotective Effect of Dabigatran With Low-Molecular-Weight Heparin.
Topics: Animals; Biomarkers; Dabigatran; Dipeptidases; Heparin, Low-Molecular-Weight; Kidney; Kidney Diseases; Male; Malondialdehyde; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2016 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
Possible renoprotective effects of dabigatran.
Topics: Anticoagulants; Dabigatran; Humans; Kidney Diseases; Male; Venous Thrombosis | 2015 |
Dagibatran Etexilate: Is There Any Need for Coagulation Monitoring After Initiation?
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Humans; Kidney Diseases; Monitoring, Physiologic | 2015 |
Author's reply.
Topics: Anticoagulants; Dabigatran; Humans; Kidney Diseases; Male; Venous Thrombosis | 2015 |
[Pharmaceutical care of a patient with oral anticoagulation and renal impairment].
Topics: Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Kidney Diseases; Pharmaceutical Services | 2015 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Health Care Costs; Hemorrhage; Humans; Kidney Diseases; Postoperative Complications; Pyridines; United Kingdom; Venous Thromboembolism | 2010 |
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease; Creatinine; Dabigatran; Fibrinolytic Agents; Glomerular Filtration Rate; Humans; Incidence; Kidney; Kidney Diseases; Morpholines; Netherlands; Patient Selection; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes | 2011 |
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Topics: Antithrombins; Area Under Curve; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Dabigatran; Humans; Kidney Diseases; Models, Biological; Prodrugs; Pyridines | 2012 |
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.
Topics: Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Colectomy; Combined Modality Therapy; Dabigatran; Emergencies; Erythrocyte Transfusion; Factor VIIa; Fatal Outcome; Female; Hemostatics; Humans; Kidney Diseases; Male; Plasma; Postoperative Hemorrhage; Recombinant Proteins; Renal Dialysis; Resuscitation; Thrombophilia | 2012 |
[Wünderlich syndrome in patient anticoagulated with dabigatran].
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Carcinoma, Transitional Cell; Dabigatran; Diabetes Mellitus, Type 2; Hematoma; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Nephrectomy; Pulmonary Disease, Chronic Obstructive; Retroperitoneal Space; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2013 |